{
  "prompt": {
    "guidelineId": "cg1127-neonatal-abstinence-scoring-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 6543
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Neonatal Abstinence Syndrome Assessment and Management\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not explicitly mention a specific publishing organization or institution like NHS, NICE, WHO, RCOG, etc. Therefore, I cannot identify a specific organization name from the provided guideline text\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Neonatal Abstinence Syndrome (NAS) Guideline** **Scope**: Applies to pediatric, neonatal, and midwifery staff caring for newborns at risk of NAS due to maternal substance use. **Key Responsibilities**: - Staff must follow guidelines, use professional judgment, and ensure accessibility. - Monitor for withdrawal symptoms using scoring tools. **Substance Effects**: - **Opiates**: Risk of premature birth, low birth weight; avoid pethidine/diamorphine in labor. - **Benzodiazepines**: Withdrawal may occur late (10 days–6 weeks); treat with chlorpromazine. - **Alcohol**: Phenobarbitone may be needed. - **Others**: Cannabis (mild symptoms), cocaine (placental abruption), nicotine (low birth weight). **Management**: - **Antenatal**: Counsel parents, refer to social services, offer Hepatitis B vaccine if needed. - **Postnatal**: Observe for ≥2 days; keep parent and baby together. - **Pharmacological Treatment**: - **Opiate withdrawal**: Start morphine (125 mcg/kg/day); wean based on NAS scores. - **Non-opiate withdrawal**: Phenobarbitone (alcohol), chlorpromazine (benzodiazepines). **Discharge Criteria**: Stable NAS scores, normal feeding/sleeping, no morphine changes for 36 hours. Ensure social support and follow-up. **Patient Information**: Provide counseling and leaflets on NAS monitoring. **Audit**: Ensure compliance with antenatal plans, NAS scoring, and discharge protocols\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T21-48-29",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"cg1127-neonatal-abstinence-scoring-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 6543\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Neonatal Abstinence Syndrome Assessment and Management\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not explicitly mention a specific publishing organization or institution like NHS, NICE, WHO, RCOG, etc. Therefore, I cannot identify a specific organization name from the provided guideline text\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Neonatal Abstinence Syndrome (NAS) Guideline** **Scope**: Applies to pediatric, neonatal, and midwifery staff caring for newborns at risk of NAS due to maternal substance use. **Key Responsibilities**: - Staff must follow guidelines, use professional judgment, and ensure accessibility. - Monitor for withdrawal symptoms using scoring tools. **Substance Effects**: - **Opiates**: Risk of premature birth, low birth weight; avoid pethidine/diamorphine in labor. - **Benzodiazepines**: Withdrawal may occur late (10 days–6 weeks); treat with chlorpromazine. - **Alcohol**: Phenobarbitone may be needed. - **Others**: Cannabis (mild symptoms), cocaine (placental abruption), nicotine (low birth weight). **Management**: - **Antenatal**: Counsel parents, refer to social services, offer Hepatitis B vaccine if needed. - **Postnatal**: Observe for ≥2 days; keep parent and baby together. - **Pharmacological Treatment**: - **Opiate withdrawal**: Start morphine (125 mcg/kg/day); wean based on NAS scores. - **Non-opiate withdrawal**: Phenobarbitone (alcohol), chlorpromazine (benzodiazepines). **Discharge Criteria**: Stable NAS scores, normal feeding/sleeping, no morphine changes for 36 hours. Ensure social support and follow-up. **Patient Information**: Provide counseling and leaflets on NAS monitoring. **Audit**: Ensure compliance with antenatal plans, NAS scoring, and discharge protocols\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}